Preclinical studies have demonstrated the anti-tumor activity of SRC inhibitors in several cancers, including prostate, colon, breast, and ovarian [28,29,30], but their efficacy in clinical trials has not been adequate as single agents for recurrent high-grade serous ovarian cancer (HGSOC), with only 21% of patients being progression-free after 6 months [31,32]. Here, SRC is linked to neoplasm.